BR112013007329A2 - método para diagnostificar o estado de doença de lyme em um mamífero, e, composição - Google Patents

método para diagnostificar o estado de doença de lyme em um mamífero, e, composição

Info

Publication number
BR112013007329A2
BR112013007329A2 BR112013007329A BR112013007329A BR112013007329A2 BR 112013007329 A2 BR112013007329 A2 BR 112013007329A2 BR 112013007329 A BR112013007329 A BR 112013007329A BR 112013007329 A BR112013007329 A BR 112013007329A BR 112013007329 A2 BR112013007329 A2 BR 112013007329A2
Authority
BR
Brazil
Prior art keywords
mammal
burgdorferi
lyme disease
composition
disease state
Prior art date
Application number
BR112013007329A
Other languages
English (en)
Portuguese (pt)
Inventor
Bettina Wagner
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of BR112013007329A2 publication Critical patent/BR112013007329A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112013007329A 2010-09-27 2011-09-27 método para diagnostificar o estado de doença de lyme em um mamífero, e, composição BR112013007329A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38669410P 2010-09-27 2010-09-27
PCT/US2011/053359 WO2012047607A2 (en) 2010-09-27 2011-09-27 Methods for diagnosing lyme disease

Publications (1)

Publication Number Publication Date
BR112013007329A2 true BR112013007329A2 (pt) 2016-07-19

Family

ID=45928310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013007329A BR112013007329A2 (pt) 2010-09-27 2011-09-27 método para diagnostificar o estado de doença de lyme em um mamífero, e, composição

Country Status (11)

Country Link
US (1) US8946393B2 (enExample)
EP (1) EP2622346A4 (enExample)
JP (1) JP2013539032A (enExample)
KR (1) KR20130101067A (enExample)
CN (1) CN103229055A (enExample)
BR (1) BR112013007329A2 (enExample)
CA (1) CA2812759A1 (enExample)
MX (1) MX2013003609A (enExample)
RU (1) RU2013118647A (enExample)
WO (1) WO2012047607A2 (enExample)
ZA (1) ZA201302402B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT106942B (pt) 2013-05-15 2020-09-10 STAB VIDA, Investigação e Serviços em Ciências Biológicas, Lda Biochip (1) e bouquet de 16 antigénios (2) para a deteção da doença de lyme aguda e crónica
WO2016025331A1 (en) * 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
CN104374921B (zh) * 2014-11-21 2016-09-07 安徽医科大学 一种用于莱姆病鞭毛抗原免疫血清学诊断的蛋白质芯片及其制备方法和应用
WO2017053167A1 (en) * 2015-09-25 2017-03-30 Qiagen Sciences Llc Compositions and methods for diagnosing lyme disease and for predicting lyme disease spirochete elimination after treatment
CN105524989A (zh) * 2015-12-31 2016-04-27 中国疾病预防控制中心传染病预防控制所 用于检测莱姆病螺旋体的rpa引物和探针及检测方法
CN105628918A (zh) * 2016-02-04 2016-06-01 浙江大学 一种蜱传莱姆病伯氏疏螺旋体检测试剂及应用
US20220034880A1 (en) * 2018-10-01 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University High specificity and sensitivity immunosorbent diagnostic assays with simultaneous resolution of multiple antibody isotypes
CA3164344A1 (en) * 2020-01-10 2021-07-15 Samantha Chang Test strip with structured substrate for multiplex lateral flow assay for disease diagnostics
WO2021211637A1 (en) * 2020-04-13 2021-10-21 Id-Fish Technology, Inc. Detection of lyme disease
US20230324382A1 (en) * 2022-02-01 2023-10-12 Trustees Of Tufts College Antiphospholipid antibodies for the diagnosis of lyme disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6300101B1 (en) 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) * 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US5620862A (en) 1993-11-24 1997-04-15 University Of Connecticut Methods for diagnosing early Lyme disease
US6316005B1 (en) * 1994-04-11 2001-11-13 Solvay Animal Health, Inc. Borrelia burgdorferi bacterin
US5558993A (en) * 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
CN1159831A (zh) * 1994-08-17 1997-09-17 马克斯·普朗克促进科学协会 含有布氏疏螺旋体ospg的疫苗
US5853987A (en) * 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
EP0880543A4 (en) 1995-10-26 2000-08-02 Rhode Island Education ANTIGENS AS VACCINE CANDIDATES FOR THE SPICK-INDUCED LYME DISEASE SPIROCHETES (BORRELIA BURGDORFERI) BY TICK VECTORS (IXODES SCAPULARIS)
CA2253374C (en) * 1996-05-02 2004-07-20 Marianne Jartved Mathiesen Novel osp-c derived peptide fragments
US6716574B2 (en) * 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US6902893B1 (en) 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
CA2294701C (en) 1997-06-30 2009-09-08 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6610838B1 (en) * 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
WO2000006745A1 (en) 1998-07-31 2000-02-10 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
DE69912827T2 (de) * 1998-09-29 2004-10-21 Loke Diagnostics Aps Aarhus "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
WO2000078800A2 (en) * 1999-06-18 2000-12-28 Medimmune, Inc. Combined decorin binding protein and outer surface protein compositions and methods of use
US20030134345A1 (en) * 2001-07-17 2003-07-17 Michael Brunner Serological assay for detection of antigens sequested within immune complexes
FI112544B (fi) * 2001-11-26 2003-12-15 Bortech Oy Menetelmä varhais- ja myöhäisvaiheen Lymen borrelioosin diagnosoimiseksi
AU2003304145A1 (en) 2002-10-18 2004-12-13 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
EP1768688A4 (en) * 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
US7390626B2 (en) 2005-02-25 2008-06-24 Immunosciences Lab., Inc. Methods and kit for diagnosing tick borne illnesses
EP1957520A4 (en) * 2005-11-29 2009-05-27 Univ Virginia Commonwealth POLYVALENTIC CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN
CN101374858A (zh) * 2005-11-29 2009-02-25 弗吉尼亚州立大学 多价嵌合ospc疫苗原及诊断抗原
WO2007133623A2 (en) 2006-05-10 2007-11-22 Biopeptides Corporation Peptide diagnostic agent for lyme disease
AU2007295927A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
US8247181B2 (en) 2007-09-07 2012-08-21 The Regents Of The University Of California Borrelia diagnostics and screening methods
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US8565892B2 (en) * 2009-10-31 2013-10-22 Qteris, Inc. Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment
WO2011068844A1 (en) 2009-12-01 2011-06-09 Temple Douglas Borrelia burgdorferi bacterial antigen diagnostic test using polymeric bait containing capture particles
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics

Also Published As

Publication number Publication date
MX2013003609A (es) 2013-10-17
EP2622346A2 (en) 2013-08-07
CA2812759A1 (en) 2012-04-12
CN103229055A (zh) 2013-07-31
WO2012047607A3 (en) 2012-08-16
RU2013118647A (ru) 2014-11-10
ZA201302402B (en) 2014-06-25
US20130273572A1 (en) 2013-10-17
EP2622346A4 (en) 2014-04-16
KR20130101067A (ko) 2013-09-12
JP2013539032A (ja) 2013-10-17
US8946393B2 (en) 2015-02-03
WO2012047607A2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
BR112013007329A2 (pt) método para diagnostificar o estado de doença de lyme em um mamífero, e, composição
CL2016001134A1 (es) Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.
Sousa et al. Molecular and serological detection of tick-borne pathogens in dogs from an area endemic for Leishmania infantum in Mato Grosso do Sul, Brazil
BR112017010268A2 (pt) agente de ligação; composição de diagnóstico; kit de diagnóstico; métodos de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral; para descartar uma infecção bacteriana em um indivíduo; para descartar uma infecção viral em um indivíduo; para considerar uma infecção bacteriana em um indivíduo; para considerar uma infecção viral em um indivíduo; para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo; para fornecer uma recomendação de tratamento para um indivíduo; para fornecer uma recomendação de teste de diagnóstico para um indivíduo; para descartar uma doença infecciosa; para identificação do tipo de infecção; e dispositivo para o diagnóstico de infecções bacterianas
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112014010718A2 (pt) métodos e sistemas para detecção de analito em amostra
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
BR112012007365A2 (pt) proteínas de ligação à il-1
BR112013004579A2 (pt) proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112014021477A2 (pt) anticorpos para metaloproteinase de matriz 9
JP2013539032A5 (enExample)
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
EP2585826A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL FAILURE
Moming et al. Mapping of B-cell epitopes on the N-terminal and C-terminal segment of nucleocapsid protein from Crimean-Congo hemorrhagic fever virus
PE20160657A1 (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto
MX2017005126A (es) Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal.
BR112014020513A2 (pt) Métodos e sistemas para amplificação de sinal de bioensaios
Pennisi et al. Serological and molecular prevalence of Leishmania infantum infection in cats from Southern Italy
WO2015023503A3 (en) Compositions and methods for multimodal analysis of cmet nucleic acids
BR112014004261B8 (pt) Diagnósticos de vacina melhorada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.